2026-06-30T02:51:40Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/66872024-09-27T09:09:28Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud author Padron-Barthe, Laura author Villalba-Orero, Maria author Gomez-Salinero, Jesus M. author Acin-Perez, Rebeca author Cogliati, Sara author Lopez-Olaneta, Marina author Ortiz-Sanchez, Paula author Bonzon-Kulichenko, Elena author Vazquez, Jesus author Garcia-Pavia, Pablo author Rosenthal, Nadia author Enriquez, Jose Antonio author Lara-Pezzi, Enrique funder Unión Europea. Comisión Europea funder Ministerio de Economía y Competitividad (España) funder Instituto de Salud Carlos III funder Comunidad de Madrid (España) funder Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) funder Fundación ProCNIC 2018-11-22T08:10:53Z 2018-11-22T08:10:53Z 2018 J Am Coll Cardiol. 2018; 71(6):654-667 10.1016/j.jacc.2017.11.067 1558-3597 0735-1097 Journal of the American College of Cardiology 29420962 http://hdl.handle.net/20.500.12105/6687 BACKGROUND In response to pressure overload, the heart develops ventricular hypertrophy that progressively decompensates and leads to heart failure. This pathological hypertrophy is mediated, among others, by the phosphatase calcineurin and is characterized by metabolic changes that impair energy production by mitochondria. OBJECTIVES The authors aimed to determine the role of the calcineurin splicing variant CnA beta 1 in the context of cardiac hypertrophy and its mechanism of action. METHODS Transgenic mice overexpressing CnAb1 specifically in cardiomyocytes and mice lacking the unique C-terminal domain in CnA beta 1 (CnA beta 1(Delta i12) mice) were used. Pressure overload hypertrophy was induced by transaortic constriction. Cardiac function was measured by echocardiography. Mice were characterized using various molecular analyses. RESULTS In contrast to other calcineurin isoforms, the authors show here that cardiac-specific overexpression of CnA beta 1 in transgenic mice reduces cardiac hypertrophy and improves cardiac function. This effect is mediated by activation of serine and one-carbon metabolism, and the production of antioxidant mediators that prevent mitochondrial protein oxidation and preserve ATP production. The induction of enzymes involved in this metabolic pathway by CnAb1 is dependent on mTOR activity. Inhibition of serine and one-carbon metabolism blocks the beneficial effects of CnA beta 1. CnA beta 1(Delta i12) mice show increased cardiac hypertrophy and declined contractility. CONCLUSIONS The metabolic reprogramming induced by CnAb1 redefines the role of calcineurin in the heart and shows for the first time that activation of the serine and one-carbon pathway has beneficial effects on cardiac hypertrophy and function, paving the way for new therapeutic approaches. (J Am Coll Cardiol 2018; 71: 654-67) (C) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/). eng Cardiac function Cell signaling Hypertrophy Metabolism Activation of Serine One-Carbon Metabolism by Calcineurin A beta 1 Reduces Myocardial Hypertrophy and Improves Ventricular Function journal article URL https://repisalud.isciii.es/bitstreams/13f50fcf-c0f5-497d-b83c-940db9796443/download File MD5 0a598397ab2a222ee103ec564b0d4b1c 3324442 application/pdf ActivationOfSerineOneCarbon_2018.pdf URL https://repisalud.isciii.es/bitstreams/125bccf0-29ac-4cb6-9c9b-17a9fa199926/download File MD5 cbde56b7c3b07b62e541fa3a7ba0288f 50718 text/plain ActivationOfSerineOneCarbon_2018.pdf.txt